Novo Nordisk submitted a high‑dose formulation of its GLP‑1 obesity drug Wegovy to the FDA and invoked an awarded priority review voucher to accelerate the agency’s clock. The submission aims to expand dosing options for weight management and piggybacks on the company’s broader GLP‑1 portfolio. Separately, CMS commentary and reporting flagged that Novo’s prior ‘most favored nation’ (MFN) pricing deal may supersede Inflation Reduction Act (IRA) negotiated prices for semaglutide products in some contexts, sparking questions about how negotiated federal prices and bilateral pricing agreements interact. Policymakers and payers are watching how these pricing mechanisms influence net pricing and access. The filings and pricing discussions underline ongoing regulatory and reimbursement complexity for GLP‑1 drugs as market uptake and policy interventions converge on blockbuster obesity and diabetes therapeutics.